Investing.com -- Novo Nordisk (CSE: NOVOb) (NYSE: NVO) shares slumped Wednesday after Roche (SIX: ROG) struck a $5.3 billion ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

President Donald Trump's nominee to lead the agency overseeing Medicare should divest financial ties to healthcare and ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and ...

Novo Nordisk A/S, Blackstone, BlackRock, Apollo Global Management, Welltower, Prologis, and Ventas are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide in people with obesity or overweight and type 2 diabetes led to a 15.7% ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...